A Phase I Study to Evaluate LSALT Peptide
NCT03772678
·
clinicaltrials.gov ↗
EARLY_PHASE1
Phase
COMPLETED
Status
52
Enrollment
INDUSTRY
Sponsor class
Conditions
None - Study is to Determine Safety in Healthy Participants
Interventions
DRUG:
LSALT peptide
OTHER:
0.9% Saline
Sponsor
Arch Biopartners Inc.